Nelfinavir mesylate

그림문자(GHS)

• 그림문자(GHS)

  

• 신호 어

  Warning

• 유해·위험 문구

  H413：장기적 영향에 의해 수생생물에 유해의 우려가 있음

• 예방조치문구

  P273：환경으로 배출하지 마시오.

  P501：...에 내용물 / 용기를 폐기 하시오.

Nelfinavir mesylate 화학적 특성, 용도, 생산

• 개요

  Viracept was launched in the US as an orally-available, non-peptidic HIV protease inhibitor. It is prepared in an eight step synthesis beginning with N- (benzyloxycarbonyl)-L-serine β-lactone. The HIV protease inhibitory activity blocks the processing of gag and gagpol polyproteins that are required for viral maturation. It was discovered based on an experimentally derived 3D-structure of HIV-1 protease. Viracept has a high oral bioavailability, lacks toxicity, and has a resistance profile different from other protease inhibitors. Viracept with ziduvudine and larnivudine generated a 98% mean reduction from baseline in viral load after 24 weeks compared to ziduvudine and larnivudine alone. Viracept also had better CD4 counts and is available in adult and pediatric formulations.

• 화학적 성질

  White Powder

• 용도

  Nelfinavir Mesylate is an antiviral. HIV protease inhibitor. It is a COVID19-related research product.

• 정의

  ChEBI: A methanesulfonate (mesylate) salt prepared from equimolar amounts of nelfinavir and methanesulfonic acid. It is used for treatment of HIV and also exhibits some anticancer properties.

• 생물학적 활성

  Orally active human immunodeficiency virus protease inhibitor. Potently inhibits HIV-1 protease (K i = 2 nM) in vitro .

Nelfinavir mesylate 공급 업체

Global(274)Suppliers

Nelfinavir mesylate 관련 검색